Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.63 -0.11 (-2.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Cash & Equivalents (2020 - 2026)

Updated

Taysha Gene Therapies (TSHA) recorded Cash & Equivalents of $455.41 million in Q2 2026, up 45.6% from $312.76 million a year earlier and up 64.6% from the prior quarter.

Analysis

Taysha Gene Therapies (TSHA) Cash & Equivalents (2020 - 2026) Analysis & Trends

At the end of FY2025, Taysha Gene Therapies reported Cash & Equivalents of $319.77 million, up 130.0% from FY2024.

  • Annual Cash & Equivalents has a five-year compound annual growth rate of 4.9% (FY2020 to FY2025).
  • Across earlier years, Cash & Equivalents came in at $139.04 million in FY2024 (-3.4%), $143.94 million in FY2023 (+63.8%), $87.88 million in FY2022 (-42.1%) and $151.74 million in FY2021 (-39.6%).
  • The Q2 2026 figure is the highest quarterly Cash & Equivalents in data going back to Q3 2020.
  • On a year-over-year basis, Cash & Equivalents has increased for five consecutive quarters, with growth averaging 58.6% over the last eight quarters.
  • Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 344.7% in Q3 2023, against a decline of 80.7% in Q3 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $276.6 million (Q1 2026), $319.77 million (Q4 2025) and $297.34 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 20.42 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 6.57 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 4.89 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 3.18 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 976.00 Mn
10 Taysha Gene Therapies 1.51 Bn 1.51 Bn - 455.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 455.41 Mn
Mar 31, 2026 276.60 Mn
Dec 31, 2025 319.77 Mn
Sep 30, 2025 297.34 Mn
Jun 30, 2025 312.76 Mn
Mar 31, 2025 116.59 Mn
Dec 31, 2024 139.04 Mn
Sep 30, 2024 157.69 Mn
Jun 30, 2024 172.74 Mn
Mar 31, 2024 123.98 Mn
Dec 31, 2023 143.94 Mn
Sep 30, 2023 164.28 Mn
Jun 30, 2023 45.08 Mn
Mar 31, 2023 63.43 Mn
Dec 31, 2022 87.88 Mn
Sep 30, 2022 36.94 Mn
Jun 30, 2022 68.88 Mn
Mar 31, 2022 99.27 Mn
Dec 31, 2021 151.74 Mn
Sep 30, 2021 191.41 Mn
API Access

Taysha Gene Therapies Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=TSHA&period=max&api_key=YOUR_API_KEY